Myelofibrosis Research Review, Issue 2
In this issue:
MANIFEST-2: Front-line pelabresib plus ruxolitinib promising
Optimal ruxolitinib dosing linked to improved outcomes
Outcome of splenectomy in JAK2 inhibitor treated patients
New machine learning model may enhance transplant risk stratification
Incorporation of molecular aberrations into risk stratification improves transplant decisions
Anti-fibrotic activity of PXS-5505 in advanced myelofibrosis
Pre-transplant ruxolitinib not associated with increased risk for GvHD
Post-transplant JAK2 V617F surveillance aids in the prediction of relapse
Expert contributor
Dr Jacinta Perram
Dr Jacinta Perram is a clinical, laboratory and transplant haematologist with an interest in myeloproliferative diseases. She has completed fellowships in transplant and CAR-T therapy and has extensive clinical research experience.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.